Vivet Therapeutics

Vivet Therapeutics is a private, clinical-stage gene therapy company based in Paris, developing a pipeline of liver-directed AAV-based treatments for rare metabolic diseases such as Wilson's Disease, Cerebrotendinous Xanthomatosis (CTX), and Progressive Familial Intrahepatic Cholestasis (PFIC). A key differentiator is its VTX-PID platform, an imlifidase-based technology designed to deplete neutralizing antibodies against AAV, potentially enabling treatment for a broader patient population and allowing for re-dosing. The company has advanced its lead program, VTX-801 for Wilson's Disease, into clinical trials and has secured Orphan Drug designations from major regulatory agencies, supported by a seasoned leadership team and committed international investors.

AAV-based gene delivery (serotype 3B) and VTX-PID, a proprietary imlifidase-based platform to transiently deplete neutralizing antibodies against AAV, enabling treatment in seropositive patients and potential re-dosing.

Vivet competes with other gene therapy developers targeting rare liver diseases (e.g., Ultragenyx, LogicBio) and with alternative treatment modalities. Its VTX-PID platform faces competition from other approaches to overcome AAV immunity, such as capsid engineering, immunosuppression regimens, or plasma apheresis. Differentiation lies in its specific AAV3B focus and the direct enzymatic clearance of antibodies.